Over 55 million people worldwide were suffering of dementia in 2020. This number is expected to almost double every 20 years, reaching 78 million in 2030 and rising to 139 million in 2050.4 The worldwide cost of dementia is estimated at US$1.3 trillion and is expected to rise to US$ 2.8 trillion by 2030.
Alzheimer’s disease (AD) remains an area of severe unmet need and decades of research, but significant progress was recently made with innovative treatments. Following the FDA approval aducanumab (Leqembi™) from Eisai and donanenab-azbt (Kisunla™) from Eli Lilly1,2 aiming at addressing underlying disease biology are now marketed. Similarly, impactful advancement was made in the discovery and the validation of laboratory tests to assist with disease diagnostics and to evaluate disease progression.
Download our insight brief and learn about the potential to advance Alzheimer’s Disease trials through advanced neurodegenerative disease reference testing services and validation of innovative diagnostic biomarkers.
Authors:
PATRICE HUGO, Ph. D., Chief Scientific Officer, IQVIA Laboratories and R&DS Design and Deliver Innovation
MAREK BIENIEK, MD, MS, Sr. Director Medical Strategy, CNS Center of Excellence, R&DS Design and Delivery Innovation
Complete the form below to access this insight brief
